Cargando…

Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial

BACKGROUND: The aim of this prospective placebo-controlled pilot study was to evaluate short-term effects of a mouthrinse containing aluminium triformate (ATF) on gingival inflammation and plaque formation in periodontal patients who are in the maintenance phase. ATF has styptic (astringent) and ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Azaripour, Adriano, Weusmann, Jens, Eschig, Carl, Schmidtmann, Irene, Van Noorden, Cornelis J. F., Willershausen, Brita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878033/
https://www.ncbi.nlm.nih.gov/pubmed/27216479
http://dx.doi.org/10.1186/s12903-016-0214-z
_version_ 1782433499228143616
author Azaripour, Adriano
Weusmann, Jens
Eschig, Carl
Schmidtmann, Irene
Van Noorden, Cornelis J. F.
Willershausen, Brita
author_facet Azaripour, Adriano
Weusmann, Jens
Eschig, Carl
Schmidtmann, Irene
Van Noorden, Cornelis J. F.
Willershausen, Brita
author_sort Azaripour, Adriano
collection PubMed
description BACKGROUND: The aim of this prospective placebo-controlled pilot study was to evaluate short-term effects of a mouthrinse containing aluminium triformate (ATF) on gingival inflammation and plaque formation in periodontal patients who are in the maintenance phase. ATF has styptic (astringent) and anti-inflammatory effects. METHODS: Forty non-smoking periodontal patients with modified sulcus bleeding index (MSBI) ≥40 % were randomly divided into two groups. The participants received a masked mouthrinse (ATF or placebo) and were instructed with the rinsing protocol of 3 daily rinses during 30 s for 7 days. One blinded investigator (CE) performed all clinical examinations. The primary outcome was reduction in gingival inflammation as measured by MSBI. The secondary outcomes were reduction of the amount of plaque as measured by plaque index (PI) and approximal plaque index (API) and the occurrence of side effects. The patients were evaluated at the start and the end of the rinsing period, including the compliance of the patients. RESULTS: MSBI was reduced in both groups compared to baseline, but the ATF group showed significantly more reduction in MSBI compared to the placebo group (ATF: 17.6 %, placebo: 7.6 %, p = 0.035). ATF and placebo had no effects on dental plaque. Patients reported ATF mouthrinse not to have side effects other than oral sensation, whereas compliance of the patients was good. Almost all patients in the ATF group reported reduction of gum bleeding after 1 week of rinsing with ATF. CONCLUSIONS: This short-term pilot clinical trial is a firm basis to design a long-term controlled clinical trial to show whether ATF helps to inhibit further periodontal breakdown in maintenance patients with high MSBI. TRIAL REGISTRATION: This trial was registered in the WHO International Clinical Trials Registry Platform as DRKS00007672, date of registration: 21/01/2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12903-016-0214-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4878033
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48780332016-05-25 Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial Azaripour, Adriano Weusmann, Jens Eschig, Carl Schmidtmann, Irene Van Noorden, Cornelis J. F. Willershausen, Brita BMC Oral Health Research Article BACKGROUND: The aim of this prospective placebo-controlled pilot study was to evaluate short-term effects of a mouthrinse containing aluminium triformate (ATF) on gingival inflammation and plaque formation in periodontal patients who are in the maintenance phase. ATF has styptic (astringent) and anti-inflammatory effects. METHODS: Forty non-smoking periodontal patients with modified sulcus bleeding index (MSBI) ≥40 % were randomly divided into two groups. The participants received a masked mouthrinse (ATF or placebo) and were instructed with the rinsing protocol of 3 daily rinses during 30 s for 7 days. One blinded investigator (CE) performed all clinical examinations. The primary outcome was reduction in gingival inflammation as measured by MSBI. The secondary outcomes were reduction of the amount of plaque as measured by plaque index (PI) and approximal plaque index (API) and the occurrence of side effects. The patients were evaluated at the start and the end of the rinsing period, including the compliance of the patients. RESULTS: MSBI was reduced in both groups compared to baseline, but the ATF group showed significantly more reduction in MSBI compared to the placebo group (ATF: 17.6 %, placebo: 7.6 %, p = 0.035). ATF and placebo had no effects on dental plaque. Patients reported ATF mouthrinse not to have side effects other than oral sensation, whereas compliance of the patients was good. Almost all patients in the ATF group reported reduction of gum bleeding after 1 week of rinsing with ATF. CONCLUSIONS: This short-term pilot clinical trial is a firm basis to design a long-term controlled clinical trial to show whether ATF helps to inhibit further periodontal breakdown in maintenance patients with high MSBI. TRIAL REGISTRATION: This trial was registered in the WHO International Clinical Trials Registry Platform as DRKS00007672, date of registration: 21/01/2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12903-016-0214-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-23 /pmc/articles/PMC4878033/ /pubmed/27216479 http://dx.doi.org/10.1186/s12903-016-0214-z Text en © Azaripour et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Azaripour, Adriano
Weusmann, Jens
Eschig, Carl
Schmidtmann, Irene
Van Noorden, Cornelis J. F.
Willershausen, Brita
Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial
title Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial
title_full Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial
title_fullStr Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial
title_full_unstemmed Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial
title_short Efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial
title_sort efficacy of an aluminium triformate mouthrinse during the maintenance phase in periodontal patients: a pilot double blind randomized placebo-controlled clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878033/
https://www.ncbi.nlm.nih.gov/pubmed/27216479
http://dx.doi.org/10.1186/s12903-016-0214-z
work_keys_str_mv AT azaripouradriano efficacyofanaluminiumtriformatemouthrinseduringthemaintenancephaseinperiodontalpatientsapilotdoubleblindrandomizedplacebocontrolledclinicaltrial
AT weusmannjens efficacyofanaluminiumtriformatemouthrinseduringthemaintenancephaseinperiodontalpatientsapilotdoubleblindrandomizedplacebocontrolledclinicaltrial
AT eschigcarl efficacyofanaluminiumtriformatemouthrinseduringthemaintenancephaseinperiodontalpatientsapilotdoubleblindrandomizedplacebocontrolledclinicaltrial
AT schmidtmannirene efficacyofanaluminiumtriformatemouthrinseduringthemaintenancephaseinperiodontalpatientsapilotdoubleblindrandomizedplacebocontrolledclinicaltrial
AT vannoordencornelisjf efficacyofanaluminiumtriformatemouthrinseduringthemaintenancephaseinperiodontalpatientsapilotdoubleblindrandomizedplacebocontrolledclinicaltrial
AT willershausenbrita efficacyofanaluminiumtriformatemouthrinseduringthemaintenancephaseinperiodontalpatientsapilotdoubleblindrandomizedplacebocontrolledclinicaltrial